Sabril (Vigabatrin) Patent Expiration, LOE Window & CMS Spending

Sabril (Vigabatrin) by Lundbeck: Off-Patent Genericized (AB Competition), 8 AB generics, $112.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLundbeck
FDA Application & PathwayN020427 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$112.0M
2024 Medicare Part D Spend$15.2M
2024 Medicaid Spend$96.9M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 26.1% 2-yr change)